‘Covid is all about privilege’: Trump’s care underscores health inequalities
Trump’s experience is a world away from the stressful waiting game most patients wade through after a positive test.
Related Articles
GSK myeloma medicine improves survival in trial, another step in the drug’s revival
GSK reported at #ASH2024 that its drug Blenrep helped patients live longer in a pivotal trial.
Early treatment may delay or prevent multiple myeloma in high-risk patients, according to new study
A precancerous stage known as smoldering myeloma is usually left to watchful waiting. At ASH 2024, a study found a benefit in treating certain patients…
Police detain person of interest in UnitedHealthcare CEO killing
UnitedHealthcare CEO Brian Thompson was shot and killed as he walked to his company’s investor meeting last week.
This father built a gene therapy for his son. Now comes the harder part: saving others’ children, too
Terry Pirovolakis built a gene therapy to save his son from an ultra-rare disease. Now he has become the first stop and last hope for…
Young biotech venture firm raises $500 million for its second fund
Dimension Capital has raised $500 million for its second fund.
Mandatory milk testing and a beacon in the rare-disease world
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning, I’ve got a packed,
Pharmalittle: We’re reading about a Biosecure Act setback, a judge ordering release of Covid vaccine data, and more
The BIOSECURE Act, which would restrict drugmakers from using key Chinese contract manufacturers, was left out of a defense budget bill
WHO sheds some light on factors possibly at play in DRC outbreak
The WHO has shed some light on factors possibly at play in a mysterious outbreak in the Democratic Republic of the Congo.
Biotech companies detail emerging efforts to ease ‘conditioning’ before genetic treatments
New genetic medicines for sickle cell disease were hailed as a milestone. Now researchers are working on ways to widen access to them.
Young biotech venture firm raises $500 million for its second fund
Dimension Capital has raised $500 million for its second fund.